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ABSTRACT 
Coadministration of methotrexate and nonsteroidal anti-inflammatory drugs (NSAIDs) 
can cause a pharmacokinetic interaction and a subsequent increase in blood 
methotrexate concentrations. methotrexate and most NSAIDs are excreted into urine 
via organic anion transporter 3 (OAT3). The purpose of this study was to evaluate 
NSAIDs that compete less with methotrexate by using the renal cell line stably 
expressing human OAT3 (S2-hOAT3) in vitro. We also confirmed the pharmacokinetic 
interaction of methotrexate with NSAIDs in vivo. [3H]methotrexate uptake into 
S2-hOAT3 cells was inhibited by most NSAIDs in a concentration-dependent manner, 
but aspirin, salicylate, tiaramide, and acetaminophen did not inhibit uptake. Inhibition 
by sulindac and pranoprofen was weaker at therapeutic drug concentrations. 
Furthermore, methotrexate concentrations in rat serum were significantly increased in 
a NSAID concentration–dependent manner when concentrations of coadministered 
NSAIDs increased above the Ki values obtained in the in vitro study. On the other 
hand, drugs that were not substrates of hOAT3, such as acetaminophen, did not 
interact with methotrexate. The magnitude of the pharmacokinetic interaction 
between methotrexate and NSAIDs was significantly correlated with results of the 
accumulation study in vitro and was not significantly correlated with a reduction of 
urinary creatinine excretion. In conclusion, methotrexate and most NSAIDs are 
substrates of hOAT3, and those drugs compete via hOAT3 in tubular secretion, the 
major mechanism of the interaction between methotrexate and NSAIDs. The 
accumulation study using S2-hOAT3 cells might be useful for screening of potential 
interactions between methotrexate and new NSAIDs in vivo. 
 
Keywords: methotrexate, tubular secretion, organic anion transporter, 
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1. Introduction 
Methotrexate, which inhibits dihydrofolate reductase, is widely used for cancer 
chemotherapy (Frei et al., 1975; Jackson, 1984), whereas nonsteroidal 
anti-inflammatory drugs (NSAIDs) have antipyretic and analgesic effects, achieved by 
inhibition of prostaglandin synthesis mediated by cyclooxygenases (Vane, 1971; 
Vane and Botting 1998). Although methotrexate and NSAIDs are often used 
concomitantly in clinical practice such as rheumatoid arthritis and cancer, the 
combination is reported to increase methotrexate -related adverse effects (Daly et al., 
1986; Singh et al., 1986; Tuyss et al., 1986; Frenia and Long, 1992; Tracy et al., 
1992). However, adequate control of pain is important for patients. Therefore, NSAIDs 
that do not elevate blood methotrexate levels are useful in clinical practice. 
Methotrexate is excreted into urine in almost unchanged form. Both 
methotrexate and NSAIDs are anion compounds, and their protein binding is 
approximately 45–51% and >90%, respectively (Shen and Azarnoff, 1978). The 
following mechanisms are responsible for NSAID-induced increases in methotrexate 
concentrations; i) decrease in glomerular filtration of methotrexate by NSAIDs via 
reduction of renal blood flow with inhibition of prostaglandin synthesis (Ahern et al., 
1988; Tracy et al., 1992; Murray and Brater, 1993; Brouwers and de Smet, 1994), ii) 
inhibition of methotrexate tubular secretion (Frenia and Long, 1992; Masada et al., 
1997; Uwai et al., 2000; Uwai et al., 2004; Nozaki et al., 2007b; EI-Sheikh et al., 
2007), and iii) competition for protein-binding sites (Brouwers and de Smet, 1994). In 
general, main interaction mechanism has been known to the inhibition of 
prostaglandin synthesis (Brouwers and de Smet, 1994). However, recently, in vitro 
studies have revealed many renal transporters for methotrexate and NSAIDs (Van 
Aubel et al., 2000; Takeuchi et al., 2001; Shibayama et al., 2006). Organic anion 
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transporters (OAT1, OAT3, OAT4, OAT-K1) (Masada et al., 1997; Takeuchi et al., 
2000; Takeda et al., 2002; Uwai et al., 2004), multidrug-resistance proteins (MRP2, 
MRP4) (EI-Sheikh et al., 2007; Nozaki et al., 2007 b), and reduced folate carrier 1 
(RFC-1) (Nozaki et al., 2004) are competitive sites between methotrexate and 
NSAIDs. Considering that the methotrexate main elimination route is the tubular 
secretion (Rubin et al., 1967; Nierenberg, 1983), it is speculated that the competition 
for renal transporters is important mechanism of the interaction in humans. 
Human organic anion transporter 3 (hOAT3) is expressed at the second 
portion of the proximal tubule epithelial cells localized at the basolateral membrane 
(Cha et al., 2001; Takeda et al., 2001; Nozaki et al., 2007 a). In epithelial cells, 
methotrexate is taken from vascular fluid by hOAT3 (Takeda et al., 2002), which is 
significantly inhibited by NSAIDs such as salicylate and loxoprofen (Takeda et al., 
2002; Uwai et al., 2004; Nozaki et al., 2007 b). Furthermore, the expression level of 
hOAT3 mRNA is the highest among the OAT family (Motohashi et al., 2002). It is 
speculated that competition for hOAT3 is the most important for the interaction 
between methotrexate and NSAIDs in humans (Ahern et al., 1988; Takeda et al., 
2002; Nozaki et al., 2007 b). Therefore, NSAIDs that do not disturb methotrexate 
transport via hOAT3 are useful in clinical practice. 
The purpose of this study was to evaluate the degree of competition between 
NSAIDs and methotrexate by using proximal tubule S2 cells stably expressing hOAT3 
(S2-hOAT3 cells) (Takeda et al., 2002) and then to examine the pharmacokinetic 
interaction of methotrexate with NSAIDs using rats to reveal the contribution of 
competition for tubular secretion and to evaluate the in vitro study. 
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2. METHODS 
2.1 Materials 
[3′,5′,7-3H]Methotrexate disodium salt (50.8, 22.5 Ci/mmol) was purchased from 
Moravek Biochemicals, Inc. (Brea, CA, USA), and [methoxy-14C]inulin (5–20 mCi/g) 
was from DuPont (Wilmington, DE, USA). Acetaminophen, mefenamic acid, 
diclofenac sodium, sulindac, indomethacin, etodolac, ibuprofen, naproxen, loxoprofen, 
piroxicam, and meloxicam were obtained from Sigma Chemical Co. (Tokyo, Japan). 
Aspirin and salicylate were from Wako Chemical.,Ltd. (Osaka, Japan). Pranoprofen 
(Mitsubishi Pharma Corp., Osaka, Japan) and tiaramide (Astellas Pharma Inc., Tokyo, 
Japan) were kindly provided. S2-hOAT3 cells, in which the human OAT3 gene was 
introduced into SV40-transfected mouse proximal tubule cells, were generous gifts of 
Dr. Endou (Kyorin University, Tokyo, Japan). This cell line highly and permanently 
expressed hOAT3 (Takeda et al., 2002). 
 
2.2 In vitro uptake examination 
S2-hOAT3 cells were maintained as described previously, with some modifications 
(Takeda et al., 2002). S2-hOAT3 cells were seeded in 12-well insert plates (3 μm, 
8×105 pore/cm2 BD Falcon; Becton Dickinson Co. NJ, USA) at a density of 1×105 
cells/well. Incubations were done in 0.8 ml and 2 ml of medium at apical and 
basolateral sides, respectively. These cells were grown in an incubator for 7 days at 
37°C in 5% CO2 and were fed flesh medium every 2 days. The incubation medium 
was changed to fetal bovine serum (FBS)–free medium an hour before initiation of the 
uptake examination. At first, we examined a validity of incubation time and 
[3H]methotrexate concentrations to elucidate that not reach to the steady state using 
S2-hOAT3 and S2-DNA (hOAT3-mock) cells (data not shown) (Takeda et al., 
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2002).The cells were incubated for 2 h in FBS-free medium containing 
[3H]methotrexate (26 nM), [14C]inulin, and various NSAIDs (0, 1, 10, 100 μM) at 
basolateral sides. When the uptake was finished, a 150-μL aliquot of the apical side 
medium was sampled, and its radioactivity was determined in 5 ml of ACS 
(Amersham Biosciences, England) by liquid scintillation counting. The uptake 
examination was stopped by cold phosphate-buffered saline (PBS), and the 
monolayer was rapidly washed 3 times adequately with cold PBS in each side. The 
cells in each well were dissolved with 150 μL of 1 N sodium hydroxide for 24 h at 
room temperature and were diluted to 10 times with distilled water. The radiation 
activity of each sample (150 μL) was measured using the treatment described above. 
Samples in which [14C]inulin transited to the apical side (>1% of samples) were 
excluded. Protein content of the solubilized cells was determined using the 
bicinchoninic acid assay (Pierce, Rockford, IL, USA). 
Mefenamic acid, indomethacin, sulindac, pranoprofen, loxoprofen, piroxicam, 
and meloxicam were dissolved in dimethyl sulfoxide. Acetaminophen, aspirin, 
salicylate, ibuprofen, diclofenac sodium, etodolac, and naproxen were dissolved in 
methanol. Tiaramide was dissolved in distilled water. Each drug was diluted with 
incubation medium. Adjustments were made so that the final concentration in the 
incubation medium was 0.1%. 
 
2.3 Kinetic analyses of [3H]methotrexate uptake 
Kinetic parameters were obtained by linear regression analysis using the following 
equation:  
 
1/accumulation = a × concentration of NSAID +b 
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a : slope.  b : intercept. 
 
in which the reciprocal of the percentage of accumulated methotrexate equals a 
multiplied by the NSAID concentration. 
 
2.4 In vivo pharmacokinetic examination in rats 
Male Wistar rats that weighed 250–300 g and had fasted overnight were used. 
Mefenamic acid was dissolved in 1 N sodium hydroxide and was diluted to less than 
10% with saline solution. Sulindac, pranoprofen, and acetaminophen were 
suspended with tragacanth gum. Vehicle or an NSAID—mefenamic acid (100 mg/kg) 
(Glazko, 1966), sulindac (5, 10, 50 mg/kg), pranoprofen (5, 10, 25 mg/kg), or 
acetaminophen (400, 500, 750 mg/kg) was administered perorally to each rat. After 
30 min, methotrexate (40 mg/kg) (parenteral methotrexate 50mg; Wyeth K.K. Tokyo, 
Japan) was administered as a bolus by intraperitoneal injection (He et al., 1991), and 
water (3% of body weight) was given orally to obtain enough urine. Each rat was 
housed individually in a rat metabolic cage during the experiment. 
Approximately 500 μL of blood was collected via the subclavian vein under 
light ether anesthesia 0.5, 2, 5, 8, 12, and 24 h after intraperitoneal injection of 
methotrexate. Serum samples were obtained after centrifugation at 5200×g  for 10 
min. Serum and urinary concentrations of methotrexate were determined by 
fluorescence polarization immunoassay using TDx (Abbott Japan co., Ltd, Tokyo, 
Japan). Concentrations of NSAIDs (mefenamic acid, sulindac, and pranoprofen) and 
acetaminophen were determined by high-performance liquid chromatography 
(HPLC). 
Urine samples were collected 0–2, 2–5, 5–12, and 12–24 h after 
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intraperitoneal injection of methotrexate. Supernatant fluid was obtained after 
centrifugation at 2400×g for 10 min. Methotrexate concentrations in urine were 
determined as in serum. The protocol(s) were approved by the institutional ethics 
committee 
 
2.4.1 HPLC condition 
Serum concentrations of NSAIDs (mefenamic acid, sulindac, and pranoprofen) and 
acetaminophen were determined by the following HPLC method: 
The chromatographic system (Jasco co., Tokyo, Japan) consisted of an 
880-PU intelligent pump equipped with an 880-51 two-line degasser, 851-AS 
intelligent autosampler, 875-UV intelligent UV detector, and CO-965 column oven. 
The Capcell Pak MF Ph-1 column (5-μm particle size, 150×4.6 mm ID; Shiseido 
co.,Ltd, Tokyo, Japan) was fitted with the C18 guard column (5 μm, 3.9×20 mm; 
Waters association Inc., Milford, MA,USA) under 40°C. The mobile-phase flow rate 
was maintained at 0.5 ml/min for all drugs. 
 
2.4.2 Measurement of NSAIDs (Hirai et al., 1997) 
The mobile phase was a mixture of acetonitrile and acetic acid (0.12%), 6:4 (v/v) for 
mefenamic acid and 4:6 (v/v) for sulindac and pranoprofen. The UV wavelength that 
determined mefenamic acid, sulindac, and pranoprofen was set at 340, 327, and 307 
nm, respectively. A serum volume of 50 μL was deproteinized by adding 150 μL of 
acetonitrile and vortexing for 10 seconds. After centrifugation at 12,000×g for 10 min 
in 4 °C, 20 μL of supernatant was injected onto HPLC. 
 
2.4.3 Measurement of Acetaminophen (Dawson et al., 1988) 
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The mobile phase was a mixture of methanol and acetic acid (0.12%), 25:75 (v/v). 
The UV wavelength was set at 249 nm. The sample for injection was prepared with 
methanol in the same manner as that described for NSAIDs. 
 
2.5 Statistical analysis 
Data were analyzed statistically by one-way analysis of variance followed by 
Scheffe’s post hoc test. Levels of statistical significance were assessed using the 
t-test (vs. vehicle). 
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3. RESULTS 
3.1 Inhibition of methotrexate accumulation by NSAIDs and acetaminophen in 
S2-hOAT3 cells 
We examined the inhibitory effects of various NSAIDs and acetaminophen on 
methotrexate accumulation using S2-hOAT3 cells. As shown in Fig. 1, most NSAIDs 
used— mefenamic acid, diclofenac sodium, sulindac, indomethacin, etodolac, 
ibuprofen, naproxen, pranoprofen, loxoprofen, piroxicam, and meloxicam—inhibited 
methotrexate accumulation mediated by hOAT3 in a concentration-dependent 
manner, but aspirin, salicylate, tiaramide, and acetaminophen did not inhibit 
methotrexate uptake into S2-hOAT3 cells. The Ki value for each drug was calculated 
by linear regression analysis with reciprocal of accumulation percent plot (Table 1). In 
addition, using Ki values, the degree of inhibition between methotrexate and NSAIDs 
was calculated in order to predict an inhibitory effect for each drug at therapeutic 
concentrations from the literature (Table 1). 
Furthermore, to reveal the validity of Ki values which were calculated from the 
linear regression analysis, we performed kinetic analysis using Dixon plots (Dixon 
1953). As shown in Fig. 2, mefenamic acid, sulindac, and pranoprofen inhibited 
[3H]methotrexate accumulation in S2-hOAT3 cells in a competitive manner. Ki values 
for these three drugs were 29 μM, 82 μM, and 84 μM, respectively. 
 
3.2 Interaction between methotrexate and NSAIDs in rats 
As shown in Fig. 3, serum methotrexate concentrations were significantly 
increased in proportion to the dose of NSAIDs. In mefenamic acid, the increase was 
significant by therapeutic concentration (100 mg/kg; P = 0.0091). While it was 
significant only by supra-therapeutic concentrations in sulindac (5mg/kg; P = 0.9983, 
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50 mg/kg; P = 0.0002) and pranoprofen (5mg/kg; P = 0.9664, 25 mg/kg; P = 0.0207) 
(Figs. 3 and 4). In all NSAIDs, the statistical differences became obvious when 
concentrations of NSAIDs were above the Ki values. On the other hand, 
acetaminophen which was not substrates of hOAT3 had little effect with more than 
100 times of the therapeutic concentrations (750 mg/kg; P = 0.1238) (Fig. 3). 
The percentage of methotrexate excreted in urine over 24 h was not affected 
by any drugs, but the urinary excretion of methotrexate was significantly increased 
during the period of 5–24 h (P < 0.05) when serum methotrexate concentrations were 
increased by combination with NSAIDs (mefenamic acid, sulindac, and pranoprofen) 
(Fig. 5). Most rats who received acetaminophen 750 mg/kg had anuria for 0–2 h, 
which might have caused the increase in urinary methotrexate over 2–5 h (P < 0.05). 
We examined urinary excretion of creatinine as indicator of glomerular filtration. 
As shown in Table 2, the urinary excretion of creatinine was not decreased with the 
addition of sulindac (50 mg/kg) although serum methotrexate concentrations were 
significant increased. Whereas, pranoprofen (5, 10 mg/kg) and acetaminophen (400, 
500, 750 mg/kg), which had no effect on serum methotrexate concentrations, 
decreased the creatinine excretion in urine (P < 0.05). 
 12
4. DISCUSSION 
Recently, many transporters that compete with methotrexate and NSAIDs 
have been identified (Masada et al., 1997; Takeuchi et al., 2000; Takeda et al., 2002; 
Nozaki et al., 2004; Uwai et al., 2004; EI-Sheikh et al., 2007; Nozaki et al., 2007 b). In 
particular, inhibition of tubular methotrexate secretion mediated by hOAT3 is a 
proposed mechanism (Takeda et al., 2002; Uwai et al., 2004; Nozaki et al., 2007 b). 
To evaluate the safety of NSAIDs coadministered with methotrexate, we established 
an in vitro screening system using S2-hOAT3 cells in this study. 
We examined the accumulation of [3H]methotrexate from the basolateral side 
into S2-hOAT3 cells. Aspirin, salicylate, tiaramide, and acetaminophen did not inhibit 
[3H]methotrexate uptake mediated by hOAT3, which indicates that these drugs are 
not substrates of hOAT3 (Fig. 1). Antipyrine, salicylate, and basicity drug groups did 
not compete with methotrexate, and the inhibitory effects of other NSAIDs were 
similar within the groups. Therefore, it is suggested that the interaction with 
methotrexate depends on a structural analogue. 
 Ki values were calculated for the NSAIDs that inhibited in a concentration- 
dependent manner. Moreover, the degrees of inhibition were predicted from 
maximum concentrations given in the literature (Table 1). Ki values calculated from 
linear regression analysis were changed by substrate concentrations, and these 
values were calculated with 26nM [3H]methotrexate (Table 1). On the other hand, the 
values can be calculated by Dixon plots (Dixon, 1953), which was not influenced by 
the substrate concentrations, and they were 29 μM for mefenamic acid, 82 μM for 
sulindac, and 84 μM for pranoprofen, respectively (Fig. 2). The Ki values obtained 
from the Dixon plots were closeness values to compare with linear regression 
analysis in this study. Therefore, the Ki and the degree of inhibition values calculated 
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through linear regression analysis with reciprocal of accumulation plot equation were 
satisfactorily appreciated. 
The degree of inhibition for mefenamic acid, sulindac, and pranoprofen were 
53%, 22%, and 17%, respectively. We presume that a drug at a concentration that is 
more than 50% of the degree of inhibition competes strongly with methotrexate and a 
drug at a concentration less than 50% of the degree of inhibition competes weakly. In 
addition, drugs that are not substrates of hOAT3, such as acetaminophen, do not 
interact with methotrexate. 
 
We also determined pharmacokinetic interactions between methotrexate and 
NSAIDs, including acetaminophen, in rats at the MTX concentration during a 
high-dose therapy (He et al., 1991). Serum methotrexate concentrations were 
increased in proportion to NSAID concentrations. Furthermore, the statistical 
differences became obvious when concentrations of NSAIDs were more than the Ki 
values obtained by in vitro studies (Figs. 3 and 4).Thus, our in vitro data with 
hOAT3-expressing cells can be used in evaluating renal pharmacokinetic interactions 
in rats. This finding is compatible with a previous report that the character of OAT3 in 
humans is comparable to that in rats (Matsumoto et al., 2007). Our in vitro study may 
provide useful information when we consider the pharmacokinetic drug interaction in 
humans. Although aspirin and salicylate were not substrates of hOAT3 in the present 
study, it has been reported that aspirin interacts with methotrexate in humans (Furst 
et al., 1990). Further study is needed to address this apparent discrepancy. 
Urinary excretion of methotrexate over 24 h was not statistically different when 
methotrexate was administered alone versus when it was combined with NSAIDs, 
including acetaminophen. These results are similar to those of a previous study 
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(Hwang et al., 1995). But excretion of methotrexate after 5 h was significantly 
increased with coadministration of NSAIDs (mefenamic acid; 100mg/kg, sulindac; 
50mg/kg, and pranoprofen; 25mg/kg) (vs. vehicle; P < 0.05) in our study (Fig. 5).Thus, 
the inhibitory effect was weakened when the serum NSAID concentrations were 
decreased. We think this is because that excretion of methotrexate in urine was 
strongly inhibited by high NSAID concentrations and the inhibition was weakened 
when NSAID concentrations were decreased.  
In the case of humans, the percentage of methotrexate recovery in urine was 
reported to be almost 100% (Shen and Azarnoff, 1978). On the other hand, urinary 
recovery of methotrexate in rats was relatively low in our study (28.0 ± 4.4%), which 
indicates that the majority of methotrexate accumulates in rat renal cells (Murray and 
Brater, 1993). Therefore, other transporter on apical side may also affect the urinary 
excretion of methotrexate in rats. 
 
Until now, the mechanism of this interaction has been reported to be the 
competition for protein-binding sites and/or the reduction of the glomerular filtration 
rate of MTX by NSAIDs via inhibition of prostaglandin synthesis (Ahern et al., 1988; 
Tracy et al., 1992; Murray and Brater, 1993; Brouwers and de Smet, 1994; Brouwers 
and de Smet, 1994). It has been reported that protein binding of mefenamic acid is 
low (48.0%) (Glazko, 1966) whereas that of most other NSAIDs is high (>90%) (Lin et 
al., 1987). In addition, sulindac exerts a little inhibition on cyclooxygenase in the 
kidney (Sedor et al., 1984). However, in our study, serum methotrexate 
concentrations were similarly elevated by mefenamic acid, sulindac and pranoprofen 
when their concentrations were more than their Ki values. Thus, the effects on 
competition for protein-binding sites and inhibition of cyclooxygenase in the kidney 
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were small with regard to the mechanism of the pharmacokinetic interaction between 
methotrexate and NSAIDs. Furthermore, it was elucidated that the elevation of serum 
methotrexate concentrations was not correlated with the reduction of the glomerular 
filtration (Table 2). The present data suggest that the interaction of methotrexate with 
NSAIDs involves inhibition of the transporter in proximal renal tubules. In particular, 
competition at hOAT3 from the basolateral side into renal cells might be an important 
mechanism. In this study, NSAIDs dose levels were relatively higher than clinical 
dose in humans, because they were required dose in rats to reproduce serum 
NSAIDs concentrations in clinical practice owing to the distinction of formulation and 
bioactivity between rats and humans. 
 
In conclusion, methotrexate and most NSAIDs are substrates of hOAT3 in 
S2-hOAT3 cells. The magnitude of the pharmacokinetic interaction between 
methotrexate and NSAIDs in rats can be speculated on, given the results of the 
accumulation study in vitro. Thus, when a therapeutic drug concentration is below the 
drug’s Ki value, obtained by in vitro study, the interaction with methotrexate will be 
relatively small in vivo. Therefore, our accumulation study using S2-hOAT3 cells 
might be useful for screening potential interactions between methotrexate and new 
NSAIDs in vivo. 
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Table 1. Ki value and degree of inhibition for each drug that inhibits [3H]methotrexate 
accumulation in S2-hOAT3 cells 
S2-hOAT3 cells were incubated with solution containing [3H]methotrexate at a 
concentration 26 µM for 2hr at 37℃ in the absence or presence of various drugs. Ki 
values represents a half of the accumulation compared with the absence of NSAIDs 
and the degree of inhibition(%) represents the inhibitory effect for [3H]methotrexate 
accumulation in the therapeutic drug concentrations of NSAIDs in comparison with 
the absence of NSAIDs (inhibitory effect 0).The values were determined by linear 
regression analysis from the [3H]methotrexate accumulation experiment at each 
NSAID concentration. 
 
Clinical Practice Drugs Ki (µM) Dose (mg) Cmax (µM) References 
Degree of Inhibition (%)
Acetaminophen 720 1000 28.58  Sanaka, 1999 N.D. 
Aspirin 5000 650 52.8  Siebert, 1983 N.D. 
Salicylate 2200  328.3  Siebert, 1983 N.D. 
Mefenamic acid 36 250 41.44  Glazko, 1966 53 
Diclifenac Na 68 50 3.77  Terhaag, 1991 13 
Sulindac 53 200 11.36  Kanfer, 1996 22 
Indomethacin 56 50 11.74  Caille, 1987 29 
Etodolac 360 200 55.33  Brater, 1989 16 
Ibuprofen 230 600 274.38  Pugh, 1984 51 
Naproxen 110 500 415.18  Caille, 1987 79 
Pranoprofen 88 75 19.16  Kajiyama, 1991 17 
Loxoprofen 170 60 11.73  Jhee, 2007 21 
Piroxicam 74 20 9.05  Olkkola, 1994 14 
Meloxicam 81 30 5.09  Busch, 1996 13 
Tiaromide 450 200 4.33  Klunk, 1981 N.D. 
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Table 2. Effects of NSAIDs and acetaminophen on creatinine excretion in urine.   
 
Dose Urinary creatinine (mg/h) Drugs (mg/kg) 0-2 2-5 5-12 12-24 (h) 
mefenamic 
acid vehicle 0.34±0.24 0.33±0.09 0.32±0.06 0.40±0.04 
 100 0.29±0.08 0.19±0.05a 0.22±0.07a 0.32±0.09 
sulindac vehicle 0.35±0.15 0.27±0.09 0.24±0.07 0.37±0.06 
 50 0.31±0.10 0.31±0.06 0.27±0.11 0.36±0.05 
 10 0.40±0.13 0.14±0.02a 0.31±0.04 0.38±0.07 
 5 0.51±0.21 0.20±0.10 0.31±0.10 0.41±0.05 
pranoprofen vehicle 0.34±0.10 0.39±0.11 0.28±0.14 0.30±0.19 
 25 0.34±0.14 0.26±0.04a 0.28±0.10 0.38±0.04 
 10 0.36±0.16 0.25±0.05a 0.31±0.12 0.39±0.10 
 5 0.53±0.14b 0.24±0.09a 0.29±0.08 0.39±0.09 
acetaminophen vehicle 0.43±0.17 0.28±0.12 0.37±0.08 0.35±0.05 
 750 0.17±0.07a 0.15±0.03a 0.12±0.08a 0.27±0.05a
 500 0.40±0.18 0.19±0.05 0.17±0.08a 0.29±0.08 
  400 0.39±0.14 0.18±0.04 0.17±0.06a 0.32±0.03 
 
Shown are means ± S.D. (n = 6). aP < 0.05 : significant low values compared with 
vehicle. 
bP < 0.05 : significant high values compared with vehicle. 
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FIGURE LEGENDS 
Fig. 1. Effects of NSAIDs and acetaminophen on [3H]methotrexate accumulation in 
S2-hOAT3 cells. Shown are means ± S.D. (n = 3). 
 
Fig. 2. Dixon plots for the effect of NSAIDs on [3H]methotrexate accumulation in 
S2-hOAT3 cells. Each plot shows means ± S.D. (n = 3). Data are expressed 
1/accumulation (pmol/mg protein). [3H]methotrexate accumulation is shown for each 
drug concentration: 10 nM (▲), 50 nM (∆), and 100 nM (●). 
 
Fig. 3. Serum methotrexate concentration after intraperitoneal injection of 
methotrexate. Each plot shows means ± S.D. (n = 6). *P < 0.05, **P < 0.01 vs. 
vehicle. 
 
Fig. 4. NSAID and acetaminophen concentrations in serum after intraperitoneal 
injection of methotrexate. Each plot shows means ± S.D. (n = 6). 
 
Fig. 5. Percentage of methotrexate excreted in urine. Shown are means ± S.D. (n = 6). 
*P < 0.05, **P < 0.01: significant high values compared with vehicle. #P < 0.05: 
significant low values compared with vehicle. 
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